CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)

Summary

The objective of this program is to allow treating physicians to supply/continue to supply Certolizumab Pegol (CIMZIA®, CZP) to adults suffering from Crohn's Disease (CD), and who are considered not suitable for treatment, intolerant, have medical contraindications or had insufficient response with an authorized conventional therapy, including other authorized biologics.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications